NZ774326A - Therapeutic antibodies and their uses - Google Patents

Therapeutic antibodies and their uses

Info

Publication number
NZ774326A
NZ774326A NZ774326A NZ77432616A NZ774326A NZ 774326 A NZ774326 A NZ 774326A NZ 774326 A NZ774326 A NZ 774326A NZ 77432616 A NZ77432616 A NZ 77432616A NZ 774326 A NZ774326 A NZ 774326A
Authority
NZ
New Zealand
Prior art keywords
lymphoma
cell
antibody
antigen binding
binding fragment
Prior art date
Application number
NZ774326A
Other versions
NZ774326B2 (en
Inventor
Arvind Rajpal
Blarcom Thomas Van
Tracy Chia-Chien Kuo
Riggers Javier Fernando Chaparro
Wei Chen
Amy Shaw-Ru Chen
Edward Derrick Pascua
Leila Marie Boustany
Yik Andy Yeung
Pavel Strop
Weihsien Ho
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55661497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ774326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Priority claimed from NZ735052A external-priority patent/NZ735052B2/en
Publication of NZ774326A publication Critical patent/NZ774326A/en
Publication of NZ774326B2 publication Critical patent/NZ774326B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to an isolated antibody, or an antigen binding fragments thereof, that specifically bind to BCMA (B­ Cell Maturation Antigen). The invention also relates to compositions comprising said anti-BCMA antibody, and methods of using the same for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease).

Claims (23)

Claims It is claimed:
1. 5 10 15 20 25 An isolated antibody, or an antigen binding fragment thereof, which specifically binds to B-Cell Maturation Antigen (BCMA), wherein the antibody comprises (a) a heavy chain variable (VH) region comprising (i) a VH complementarity determining region one (CDR1) comprising SEQ ID NO: 151, 156, or 157; (ii) a VH CDR2 comprising SEQ ID NO: 158 or 159; and (iii) a VH CDR3 comprising SEQ ID NO: 155; and (b) a light chain variable (VL) region comprising (i) a VL CDR1 comprising SEQ ID NO: 209; (ii) a VL CDR2 comprising SEQ ID NO: 221; and (iii) a VL CDR3 comprising SEQ ID NO: 225.
2. The antibody or the antigen binding fragment of claim 1, wherein the VH region comprises the sequence shown in SEQ ID NO: 112 or a variant with one or several conservative amino acid substitutions in residues that are not within a CDR and/or the VL region comprises the amino acid sequence shown in SEQ ID NO: 38 or a variant thereof with one or several amino acid substitutions in amino acids that are not within a CDR.
3. The antibody or the antigen binding fragment of claim 1 or 2, wherein the VH comprises the sequence shown in SEQ ID NO: 112 and the VL comprises the sequence shown in SEQ ID NO: 38.
4. The antibody or the antigen binding fragment of claim 2 or 3, wherein the antibody comprises a light chain comprising the sequence shown in SEQ ID NO: 357 and a heavy chain comprising the sequence shown in SEQ ID NO: 358.
5. The antibody or the antigen binding fragment of claim 1, wherein the antibody comprises a VH region produced by the expression vector with ATCC Accession No. PTA-122094.
6. The antibody or the antigen binding fragment of claim 1, wherein the antibody comprises a VL region produced by the expression vector with ATCC Accession No. PTA-122093.
7. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or antigen binding fragment of any one of claims 1-6 and a pharmaceutically acceptable carrier.
8. 5 10 15 20 25 An isolated polynucleotide comprising a nucleotide sequence encoding the antibody of any one of claims 1-6.
9.
10. A vector comprising the polynucleotide of claim 8. An isolated host cell that recombinantly produces the antibody or the antigen binding fragment of any one of claims 1-6, provided that if the cell is a human cell it is ex vivo.
11. A method of producing an antibody, comprising culturing the host cell of claim 10 under conditions that result in production of the antibody, and isolating the antibody from the host cell or culture.
12. The antibody or the antigen binding fragment of any one of claims 1-6, or the pharmaceutical composition of claim 7, for use as a medicament.
13. The antibody or the antigen binding fragment for use of claim 12, wherein the medicament is for use in the treatment of a B-cell related cancer selecting from the group consisting of multiple myeloma, malignant plasma cell neoplasm, Hodgkin’s lymphoma, nodular lymphocyte predominant Hodgkin’s lymphoma, Kahler’s disease and Myelomatosis, plasma cell leukemia, plasmacytoma, B-cell prolymphocytic leukemia, hairy cell leukemia, B-cell non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), follicular lymphoma, marginal zone lymphoma, large cell lymphoma, precursor B-lymphoblastic lymphoma, myeloid leukemia, diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, mucosa associated lymphatic tissue lymphoma, small cell lymphocytic lymphoma, mantle cell lymphoma, Burkitt lymphoma, primary mediastinal (thymic) large B-cell lymphoma, lymphoplasmactyic lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, T cell/histiocyte 5 10 15 20 25 30 rich large B-cell lymphoma, primary central nervous system lymphoma, primary cutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma associated with inflammation, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and other B-cell related lymphoma.
14. The antibody or the antigen binding fragment of any one of claims 1-6, or the pharmaceutical composition of claim 7, for use in the treatment of multiple myeloma.
15. Use of an antibody or the antigen binding fragment of any one of claims 1 6, or the pharmaceutical composition of claim 7, in the manufacture of a medicament for treating a condition associated with cells expressing BCMA in a subject.
16.
17. The use of claim 15, wherein the condition is a cancer. The use of claim 16, wherein the cancer is a B-cell related cancer selecting from the group consisting of multiple myeloma, malignant plasma cell neoplasm, Hodgkin’s lymphoma, nodular lymphocyte predominant Hodgkin’s lymphoma, Kahler’s disease and Myelomatosis, plasma cell leukemia, plasmacytoma, B-cell prolymphocytic leukemia, hairy cell leukemia, B-cell non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), follicular lymphoma, marginal zone lymphoma, large cell lymphoma, precursor B-lymphoblastic lymphoma, myeloid leukemia, diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, mucosa-associated lymphatic tissue lymphoma, small cell lymphocytic lymphoma, mantle cell lymphoma, Burkitt lymphoma, primary mediastinal (thymic) large B-cell lymphoma, lymphoplasmactyic lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, T cell/histiocyte-rich large B-cell lymphoma, primary central nervous system lymphoma, 5 10 15 20 25 primary cutaneous diffuse large B-cell lymphoma (leg type), EBV positive diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma associated with inflammation, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma unclassified with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and other B-cell related lymphoma.
18. Use of an antibody or the antigen binding fragment of any one of claims 1 6, or the pharmaceutical composition of claim 7, in the manufacture of a medicament for inhibiting tumor growth or progression in a subject who has malignant cells expressing BCMA.
19. Use of an antibody or the antigen binding fragment of any one of claims 1 6, or the pharmaceutical composition of claim 7, in the manufacture of a medicament for inhibiting metastasis of malignant cells expressing BCMA in a subject.
20. Use of an antibody or the antigen binding fragment of any one of claims 1 6, or the pharmaceutical composition of claim 7, in the manufacture of a medicament for inducing tumor regression in a subject who has malignant cells expressing BCMA.
21.
22. The use of claim 15, wherein the condition is an autoimmune disorder. The use of claim 21, wherein the autoimmune disorder is systemic lupus erythematosus or rheumatoid arthritis.
23. The antibody or antigen binding fragment of claim 1, substantially as herein described with reference to any one of the examples and/or
NZ774326A 2016-03-30 Therapeutic antibodies and their uses NZ774326B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562146843P 2015-04-13 2015-04-13
US201562146504P 2015-04-13 2015-04-13
US201662301582P 2016-02-29 2016-02-29
NZ735052A NZ735052B2 (en) 2016-03-30 Therapeutic antibodies and their uses

Publications (2)

Publication Number Publication Date
NZ774326A true NZ774326A (en) 2025-03-28
NZ774326B2 NZ774326B2 (en) 2025-07-01

Family

ID=

Also Published As

Publication number Publication date
SA517390140B1 (en) 2021-11-24
AU2022203601B2 (en) 2025-07-10
PE20221262A1 (en) 2022-08-16
AU2016248946C1 (en) 2024-10-17
PH12023550222A1 (en) 2024-03-11
SG10201912819XA (en) 2020-02-27
IL254219A0 (en) 2017-10-31
HUS2400014I1 (en) 2024-06-28
PL3988117T3 (en) 2025-03-10
US11814435B2 (en) 2023-11-14
PT3988117T (en) 2025-01-23
KR20200053642A (en) 2020-05-18
NO2025024I1 (en) 2025-05-26
NO2026008I1 (en) 2026-02-19
FI4234581T3 (en) 2025-11-24
JP6913025B2 (en) 2021-08-04
ES3012402T3 (en) 2025-04-09
EP3283106B1 (en) 2021-12-22
CN114773476A (en) 2022-07-22
EP4234581B1 (en) 2025-09-17
CA3219680A1 (en) 2016-10-13
CN119708245A (en) 2025-03-28
HUE069499T2 (en) 2025-03-28
AU2016248946A1 (en) 2017-09-21
AU2022203620A1 (en) 2022-06-16
PL4234581T3 (en) 2026-01-26
HUS2500022I1 (en) 2025-06-28
EP3988117A1 (en) 2022-04-27
US20180171018A1 (en) 2018-06-21
IL310723A (en) 2024-04-01
FR26C1010I1 (en) 2026-04-17
NZ735052A (en) 2025-03-28
CA2925329C (en) 2024-01-02
IL290496A (en) 2022-04-01
HUE057285T2 (en) 2022-04-28
NL301271I2 (en) 2026-02-17
FR24C1023I1 (en) 2024-07-26
PE20180046A1 (en) 2018-01-15
MX2022001830A (en) 2022-03-17
FR24C1023I2 (en) 2026-04-03
EP3988117B1 (en) 2024-11-27
HUE073610T2 (en) 2026-01-28
KR102110557B1 (en) 2020-05-15
MX2022001831A (en) 2022-03-17
CA3219665A1 (en) 2016-10-13
EP4647446A3 (en) 2026-02-18
CA3219684A1 (en) 2016-10-13
NZ774327A (en) 2025-03-28
WO2016166629A1 (en) 2016-10-20
SG11201707192XA (en) 2017-10-30
CN108136002A (en) 2018-06-08
BR112017019785B1 (en) 2022-11-16
ES3053863T3 (en) 2026-01-27
JP2021169486A (en) 2021-10-28
RU2017133826A3 (en) 2019-05-13
HRP20251284T1 (en) 2025-12-05
KR20200053641A (en) 2020-05-18
FI3988117T3 (en) 2025-01-27
PH12017501732A1 (en) 2018-04-02
US20180298108A1 (en) 2018-10-18
JP2023109898A (en) 2023-08-08
BR112017019785A2 (en) 2018-05-22
IL254219B (en) 2022-03-01
SG10201912823PA (en) 2020-02-27
TWI703157B (en) 2020-09-01
MY196625A (en) 2023-04-23
FIC20260009I1 (en) 2026-03-05
TWI787645B (en) 2022-12-21
AU2025248718A1 (en) 2025-10-30
PL3283106T3 (en) 2022-05-02
KR102405104B1 (en) 2022-06-07
LUC00344I1 (en) 2024-05-22
TW201706311A (en) 2017-02-16
CN114874331A (en) 2022-08-09
JP2018516068A (en) 2018-06-21
CO2017010495A2 (en) 2018-01-05
IL290488B1 (en) 2024-03-01
HK1255385A1 (en) 2019-08-16
ES2905315T3 (en) 2022-04-07
CN108136002B (en) 2022-05-31
US11155630B2 (en) 2021-10-26
CA2925329A1 (en) 2016-10-13
JP2025081581A (en) 2025-05-27
ZA201807153B (en) 2022-08-31
KR102405099B1 (en) 2022-06-07
SI4234581T1 (en) 2026-01-30
SI3988117T1 (en) 2025-03-31
US10793635B2 (en) 2020-10-06
JP2025081580A (en) 2025-05-27
EP4234581A3 (en) 2023-10-04
DK4234581T3 (en) 2025-10-06
RU2017133826A (en) 2019-05-13
US20210054087A1 (en) 2021-02-25
US20240018252A1 (en) 2024-01-18
FIC20250021I1 (en) 2025-05-27
PT3283106T (en) 2022-02-02
AU2016248946B2 (en) 2022-03-10
FIC20240014I1 (en) 2024-05-21
PT4234581T (en) 2025-11-18
TWI703159B (en) 2020-09-01
EP4647446A2 (en) 2025-11-12
US20160297885A1 (en) 2016-10-13
EP4234581A2 (en) 2023-08-30
LUC00344I2 (en) 2026-05-05
AU2022203620B2 (en) 2025-07-10
US9969809B2 (en) 2018-05-15
US10040860B2 (en) 2018-08-07
JP7641323B2 (en) 2025-03-06
DK3988117T3 (en) 2025-01-20
KR20170131699A (en) 2017-11-29
TW201811833A (en) 2018-04-01
IL310723B1 (en) 2026-07-01
EP3283106A1 (en) 2018-02-21
SI3283106T1 (en) 2022-04-29
PE20221580A1 (en) 2022-10-06
FR25C1020I1 (en) 2025-08-01
IL290488B2 (en) 2024-07-01
HRP20241757T1 (en) 2025-02-28
IL290488A (en) 2022-04-01
TW202115120A (en) 2021-04-16
US20210188991A1 (en) 2021-06-24
MX2017013297A (en) 2018-06-19
DK3283106T3 (en) 2022-01-10
AU2022203601A1 (en) 2022-06-16
CN114874331B (en) 2025-01-07
RU2722381C2 (en) 2020-05-29
PH12023550223A1 (en) 2024-03-11
CN114773476B (en) 2025-09-09

Similar Documents

Publication Publication Date Title
JP2020528750A5 (en)
KR102117202B1 (en) Combination therapy with an anti-cd19 antibody and a purine analog
RU2019138710A (en) ANTIBODIES SPECIFIC TO FLT3 AND THEIR APPLICATIONS
IL276830B2 (en) Anti-claudin 18.2 antibodies and their uses
JP2023113893A5 (en)
JP2021514664A5 (en)
JP2020521481A5 (en)
RU2756010C2 (en) Combination of cd19 antibody and bruton tyrosine kinase inhibitor and their application
JP2016526904A5 (en)
MY201816A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
FI3988117T3 (en) Therapeutic antibodies and their uses
RU2018145852A (en) ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION
RU2014106671A (en) OPTIONS OF HUMANIZED IMMUNOMODULATING MONOCLONAL ANTIBODIES
JP2018534933A5 (en)
NZ705848A (en) Anti-cd38 antibodies
JP2013520984A5 (en)
RU2019104980A (en) ANTI-ICOS ANTIBODIES
JP2014525925A5 (en)
KR20140064873A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
JP2015517512A5 (en)
RU2015108797A (en) ANTIBODIES TO JAGGED AND WAYS OF THEIR APPLICATION CROSS REFERENCE TO RELATED APPLICATIONS
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
CN114867493B (en) KIR3DL3 is an inhibitory receptor of the immune system and its uses.
NZ774326B2 (en) Therapeutic antibodies and their uses
NZ735052B2 (en) Therapeutic antibodies and their uses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAR 2027 BY THOMSON REUTERS

Effective date: 20260202